The partnership with Moderna has been very fruitful for Rovi: the laboratory has gone from earning 65.6 million euros in third-party manufacturing in 2019 to billing...
Spanish pharma companies started the year maintaining the red of the previous year. In Q1, the aggregate capitalization registered a drop of 10.57%, with values such...
The gross operating result (Ebitda) reached €97.1 million in the first half of 2023, 16% less than in the first six months of 2022. Operating income...
Rovi announced that it estimates its operating income will decrease by around 10% compared to 2023. This forecast has been justified, mainly, by the fact that...
Rovi obtained a gross operating result of €279 million in 2022. Sales of the heparin division increased by 9% in 2022 compared to 2021, up to...
The Spanish pharma sector increased 5% on the stock market in the first quarter despite the fall of Grifols. Pharma Mar was the pharmaceutical company with...